{
  "id": 188,
  "text": ", 2001, 2002; Darragh et al., 2012).Immunohistochemistry for p16 is available in many, but not all, diagnostic laboratories, and therefore the WHO classifica­ tion allows for a diagnosis of SCC not otherwise specified (NOS), in settings where the distinction between HPV-associated and HPV-independent tumours cannot be made by either p16 immu­ nostaining or HPV testing (WHO Classification of Tumours Editorial Board, 2020).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: , 2001, 2002; Darragh et al., 2012).Immunohistochemistry for p16 is available in many, but not all, diagnostic laboratories, and therefore the WHO classifica­ tion allows for a diagnosis of SCC not otherwise specified (NOS), in settings where the distinction between HPV-associated and HPV-independent tumours cannot be made by either p16 immu­ nostaining or HPV testing (WHO Classification of Tumour\n\n<question>: ",
  "ChatGPT_response_0": "在无法通过p16免疫组化或HPV测试进行区分的情况下，根据WHO分类，可以对SCC进行未明确类型（NOS）的诊断。这意味着在某些实验室无法进行p16免疫组化检测的情况下，或者在p16免疫组化或HPV测试无法区分HPV相关和HPV无关肿瘤的情况下，可以将肿瘤诊断为未明确类型的鳞状细胞癌（SCC NOS）。",
  "query": "在诊断实验室中可以通过p16免疫组化进行的HPV相关鳞状细胞癌的区分。在无法通过p16免疫组化或HPV测试进行区分的情况下，WHO分类允许对SCC进行何种诊断？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在诊断实验室中可以通过p16免疫组化进行的HPV相关鳞状细胞癌的区分。在无法通过p16免疫组化或HPV测试进行区分的情况下，WHO分类允许对SCC进行何种诊断？\n\n<reference text>: , 2001, 2002; Darragh et al., 2012).Immunohistochemistry for p16 is available in many, but not all, diagnostic laboratories, and therefore the WHO classifica­ tion allows for a diagnosis of SCC not otherwise specified (NOS), in settings where the distinction between HPV-associated and HPV-independent tumours cannot be made by either p16 immu­ nostaining or HPV testing (WHO Classification of Tumours Editorial Board, 2020).\n\n<reply>: ",
  "response": "在无法通过p16免疫组化或HPV测试进行区分的情况下，根据WHO分类，可以对SCC进行未明确类型（NOS）的诊断。这意味着在某些实验室无法进行p16免疫组化检测的情况下，或者在p16免疫组化或HPV测试无法区分HPV相关和HPV无关肿瘤的情况下，可以将肿瘤诊断为未明确类型的鳞状细胞癌（SCC NOS）。"
}